Zynex, Inc. (OTCQB: ZYXI) is engaged within the development and commercialization of FDA-cleared electrotherapy medical device. Shares of the medical device manufacturer are climbing 24.79%, through early trading on Tuesday, August 22, 2017. Over the past month, Zynex, Inc. has seen average daily volume of 60,251 shares. However, volume of 116,667 shares or dollar volume of $176,167, has already exchanged hands on Tuesday.
Shares of Zynex, Inc. are rallying today, after the Taglich Brothers announced it has initiated coverage of the medical device manufacturer. Taglich Brothers is a micro-cap broker dealer. Here is the full press release detailing of the coverage initiation:
Zynex, Inc. Press Release:
NEW YORK, NY–(Marketwired – August 22, 2017) – Taglich Brothers, Inc. announces that it has initiated coverage of Zynex, Inc. (OTCQB: ZYXI).
Zynex, Inc., headquartered in Lone Tree, Colorado provides FDA-cleared electrotherapy medical devices used for pain management and rehabilitation. The company is primarily focused on selling and marketing its NexWave and InWave electrotherapy product, as well as consumable supplies for electrotherapy products. The company operates two subsidiaries, Zynex Medical™, which provides electrotherapy devices and consumable products for home use and Zynex Monitoring Solutions™, which is developing a blood volume-monitoring device for use in hospitals and outpatient surgical centers.
The complete 17-page report is available at www.taglichbrothers.com.
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years. All research issued by Taglich Brothers, Inc. is based on public information. In July 2017, the company paid Taglich Brothers a monetary fee of $4,500 (USD) representing payment for the creation and dissemination of research reports for three months. In December 2017, the company will begin paying Taglich Brothers a monthly monetary fee of $1,500 (USD) for the creation and dissemination of research reports.